Learn more and get a better treatment plan for abdominal cancer with *precisely chosen* top experts. Visit our Online Expert Centers at
https://diagnosticdetectives.com/expe...
Professor Dr. Paul Sugarbaker MD, abdominal peritoneal metastatic cancer treatment expert, co-author of The Sugarbaker Procedure - Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy CRS HIPEC, and Dr. Anton Titov MD PhD MBA / Exclusive interview
- Before we get into more details of the Sugarbaker Procedure to treat peritoneal cancer with surgery and chemotherapy, What is the overall treatment strategy of cancer in the peritoneal space? What is a high-level picture of treatment? It is very important to assess the patient before treatment, and review prognostic indicators that tell us if this patient is likely to profit from Cytoreductive Surgeryand Hyperthermic Intraperitoneal Chemotherapy So preoperative assessment after peritoneal cancer diagnosis is very important. And it's not so easy to do, it involves the CT scans, it involves an assessment of the patient's performance status, and a review of the pathology of tumor to determine the type of cancer that has spread into peritoneal space. So preoperative assessment is extremely important. If the patient is considered by a multidisciplinary team to be a candidate for cytoreductive surgery, then they go to the operating room. Usually we first do cytoreductive surgery. Sometimes, we want to give patients a limited course of cancer chemotherapy first. We call that neoadjuvant chemotherapy. But for the most part patients go straight to the operating room. We make a big abdominal incision, and they can have 6 hours or 8 hours or 10 hours of surgery in order to remove every last speck [smallest piece] of peritoneal cancer. All the visible component of the peritoneal cancer should be removed. We call this "cytoreductive surgery", CRS, because we want to remove the cancer down to the cellular level. After cytoreductive surgery [CRS], we flood the abdomen with a large volume of warm chemotherapy solution. And that's an attempt to eradicate what we call "minimal residual disease". It is cancer cells that the surgeon does not see. What the surgeon does not see is what kills the patient. It is metastatic disease that usually kills the patient. The micro-metastases. Yes, micrometastatic disease. We are trying to get rid of those free cancer cells and micrometastatic disease with the HIPEC. Then after the HIPEC procedure the patient is followed by a multidisciplinary team to make sure that appropriate further treatment is done, based on a molecular type of cancer. That is correct. And for the most part, CRS and HIPEC is added on to the appropriate systemic chemotherapy. We add CRS and HIPEC to the patient's treatment plan, because this is a treatment in addition to systemic chemotherapy - it's not exclusive of systemic chemotherapy.
Professor Dr. Paul Sugarbaker MD, abdominal peritoneal metastatic cancer treatment expert, co-author of The Sugarbaker Procedure - Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy CRS HIPEC, and Dr. Anton Titov MD PhD MBA / Exclusive interview
- Before we get into more details of the Sugarbaker Procedure to treat peritoneal cancer with surgery and chemotherapy, What is the overall treatment strategy of cancer in the peritoneal space? What is a high-level picture of treatment? It is very important to assess the patient before treatment, and review prognostic indicators that tell us if this patient is likely to profit from Cytoreductive Surgeryand Hyperthermic Intraperitoneal Chemotherapy So preoperative assessment after peritoneal cancer diagnosis is very important. And it's not so easy to do, it involves the CT scans, it involves an assessment of the patient's performance status, and a review of the pathology of tumor to determine the type of cancer that has spread into peritoneal space. So preoperative assessment is extremely important. If the patient is considered by a multidisciplinary team to be a candidate for cytoreductive surgery, then they go to the operating room. Usually we first do cytoreductive surgery. Sometimes, we want to give patients a limited course of cancer chemotherapy first. We call that neoadjuvant chemotherapy. But for the most part patients go straight to the operating room. We make a big abdominal incision, and they can have 6 hours or 8 hours or 10 hours of surgery in order to remove every last speck [smallest piece] of peritoneal cancer. All the visible component of the peritoneal cancer should be removed. We call this "cytoreductive surgery", CRS, because we want to remove the cancer down to the cellular level. After cytoreductive surgery [CRS], we flood the abdomen with a large volume of warm chemotherapy solution. And that's an attempt to eradicate what we call "minimal residual disease". It is cancer cells that the surgeon does not see. What the surgeon does not see is what kills the patient. It is metastatic disease that usually kills the patient. The micro-metastases. Yes, micrometastatic disease. We are trying to get rid of those free cancer cells and micrometastatic disease with the HIPEC. Then after the HIPEC procedure the patient is followed by a multidisciplinary team to make sure that appropriate further treatment is done, based on a molecular type of cancer. That is correct. And for the most part, CRS and HIPEC is added on to the appropriate systemic chemotherapy. We add CRS and HIPEC to the patient's treatment plan, because this is a treatment in addition to systemic chemotherapy - it's not exclusive of systemic chemotherapy.
Cancer Spread in the Abdomen: How Patient is Evaluated for Treatment? (4) best treatment for damaged hair | |
Likes | Dislikes |
358 views views | followers |
Science & Technology | Upload TimePublished on 13 Jul 2018 |
Không có nhận xét nào:
Đăng nhận xét